ArticleSisli Etfal Hastanesi tip bulteni2025
Analysis of the Risk of Neoplasm and Malignancy of Salivary Gland Neoplasm of Uncertain Malignant Potential (SUMP): From the Perspective of Cytomorphological Subgroups.
Article in Sisli Etfal Hastanesi tip bulteni, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to investigate the risk of neoplasm (RON) and the risk of malignancy (ROM) in cases diagnosed as salivary gland neoplasm of uncertain malignant potential (SUMP), with subclassification based on cytomorphologic features. Methods: A retrospective review was conducted on salivary gland fine-needle aspiration (FNA) specimens diagnosed as SUMP between 2018 and 2022 in a tertiary care setting. Each case was re-evaluated by two pathologists and subclassified into basaloid, oncocytic, or clear cell/other categories according to the dominant cytomorphologic pattern. RON and ROM were calculated for the overall SUMP category and for each cytomorphologic subgroup. Results: Among 41 SUMP cases, the basaloid subtype was the most common (70.7%), followed by the oncocytic (19.5%) and the clear cell/others (9.8%). Histopathological confirmation was available in 65.9% of cases, all of which were neoplastic, resulting in a RON of 100%. The overall ROM was 29.6%. The ROMs by subgroup were 25% for basaloid, 40% for oncocytic, and 50% for clear cell/others. Pleomorphic adenoma was the most frequently encountered benign neoplasm (33.3%), and basal cell carcinoma was the most common malignant diagnosis (18.5%). The majority of malignant cases (87.5%) were located in the parotid gland. Conclusion: This study confirms the consistently high neoplastic potential of SUMP lesions and highlights the variation in malignancy risk among different cytomorphologic subtypes. Although the ROM differed among the subgroups, they all demonstrated clinical relevance, supporting the utility of cytomorphologic subclassification in salivary gland cytopathology. These findings may contribute to more refined risk assessment and patient management within the Milan System framework.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.